For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human E-cadherin Detection Kit is designed for detection and quantitation of human insulin in cell culture media and cell lysates using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Epithelial Cadherin (E-Cadherin), also known as Cadherin-1 or Uvomorulin (in mouse and rat) is a single-pass transmembrane protein that facilitates calcium dependent cell adhesion. A member of the Cadherin family, E-Cadherin utilizes five extracellular EC domains to form cis-clusters between adjacent epithelial cells and trans-clusters within the same cell. Cleavage of the N-terminal domain by a number of proteases is critical for cell motility and EGFR-dependent survival. The intracellular domain of E-cadherin interacts with many proteins including β-catenin, α-catenin, vinculin, and plakoglobin. Lack of binding to any of these proteins has been indicated in cancer metastasis.
|Assay Target Class||Protein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.